Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Enovis Corp, which offers orthopedic bracing, surgical implants and footcare solutions, said on Monday it had agreed to acquire Italian surgical implant manufacturer ...
In September 2023, EQT Private Equity announced the sale of LimaCorporate to the NYSE-listed Enovis Group. The transaction is expected to close in early 2024. [ 21 ]
JMP Securities initiated coverage on Enovis Corporation (NYSE:ENOV), a medical technology company focusing on orthopedics. The analyst adds that the company sells a broad portfolio of products ...
Enovis is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.
About Enovis Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive ...
Wilmington, DE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology company, announced today it will unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, alongside other advanced product offerings at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting in ...
For premium support please call: 800-290-4726 more ways to reach us
Dr. Gregory Lundeen is a consultant for Enovis™ Corporation. References. e+ testing data on file. Bench test results not necessarily indicative of clinical performance. Jennings et al. The influence of femoral condylar lift-off on the wear of artificial knee joints. Proc Inst Mech Eng [H]. 2007 Apr;221(3):305-14. S.M. Kurtz.